News

LZVO are pleased to inform you about upcoming delivery of version 6.0 for the Latvian Medicines Verification System (LZVS).

In the first quarter of 2025, 29.7 million transactions were made in the Latvian Medicines Verification System (LZVS), which is slightly more than in the corresponding period of 2024.

Representatives of Arvato Customer Group countries met with system developer Arvato Systems GmbH in Vienna, Austria, on 25 and 26 March to plan further improvements in the National Medicines Verification System.

A recent Europol report reveals that criminals are actively using digital platforms to trade counterfeit medicines across Europe. The Latvian Medicines Verification Organisation (LZVO) urges the public to purchase medicines only from registered pharmacies and medical institutions and to remain vigilant when shopping online.

On 30 January 2025, Arvato Systems held a webinar for IT developers to inform them about the planned updates to the LZVS. Updates will be introduced with the release of Core NMVS 6.0.

In line with the deployment of EU Hub Release 1.16, which will take effect on 25 January 2025, the European Medicines Verification Organisation is introducing critical changes to the structure of Product Master Data (PMD) and Product Pack Data (PPD). Additional existing fields will now become mandatory and require action to ensure compliance.